Zymeworks Past Earnings Performance
Past criteria checks 0/6
Zymeworks has been growing earnings at an average annual rate of 19.1%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 48.4% per year.
Key information
19.1%
Earnings growth rate
23.6%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 48.4% |
Return on equity | -28.8% |
Net Margin | -249.6% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zymeworks makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 50 | -126 | 69 | 1 |
31 Dec 23 | 76 | -119 | 70 | 0 |
30 Sep 23 | 462 | 205 | 87 | 0 |
30 Jun 23 | 448 | 186 | 86 | 0 |
31 Mar 23 | 446 | 173 | 80 | 0 |
31 Dec 22 | 412 | 124 | 75 | 0 |
30 Sep 22 | 30 | -224 | 49 | 0 |
30 Jun 22 | 32 | -237 | 49 | 0 |
31 Mar 22 | 28 | -240 | 53 | 0 |
31 Dec 21 | 27 | -212 | 42 | 0 |
30 Sep 21 | 22 | -211 | 50 | 0 |
30 Jun 21 | 21 | -223 | 56 | 0 |
31 Mar 21 | 31 | -194 | 49 | 0 |
31 Dec 20 | 39 | -181 | 55 | 0 |
30 Sep 20 | 25 | -215 | 72 | 0 |
30 Jun 20 | 30 | -173 | 63 | 0 |
31 Mar 20 | 26 | -163 | 62 | 0 |
31 Dec 19 | 30 | -145 | 63 | 0 |
30 Sep 19 | 57 | -64 | 40 | 0 |
30 Jun 19 | 51 | -52 | 36 | 0 |
31 Mar 19 | 65 | -29 | 31 | 0 |
31 Dec 18 | 53 | -37 | 30 | 0 |
30 Sep 18 | 74 | -13 | 28 | 0 |
30 Jun 18 | 72 | -11 | 26 | 0 |
31 Mar 18 | 52 | -16 | 19 | 0 |
31 Dec 17 | 52 | -11 | 18 | 0 |
30 Sep 17 | 4 | -55 | 19 | 0 |
30 Jun 17 | 6 | -51 | 16 | 0 |
31 Mar 17 | 11 | -47 | 17 | 0 |
31 Dec 16 | 11 | -34 | 13 | 0 |
30 Sep 16 | 10 | -30 | 9 | 0 |
31 Dec 15 | 10 | -19 | 5 | 0 |
31 Dec 14 | 2 | -13 | 4 | 0 |
Quality Earnings: ZA8 is currently unprofitable.
Growing Profit Margin: ZA8 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZA8 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.1% per year.
Accelerating Growth: Unable to compare ZA8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZA8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ZA8 has a negative Return on Equity (-28.76%), as it is currently unprofitable.